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INTRODUCTION
Prostate cancer (PCa) is the leading cancer among men in the United States, and is a disease with strong genetic susceptibility. The genetic susceptibility is due to the inheritance of altered germline DNA sequences, either in the form of point mutations such as single nucleotide polymorphisms (SNPs), or deletions/gains of a string of nucleotides such as copy number polymorphisms (CNPs). Most current genetic studies focus only on the role of SNPs in genetic susceptibility. In contrast, few studies have explored the role of deletions/gains in cancer predisposition, due to limited methods. In fact, germline deletions/gains are common in the human genome and may have a significant impact on gene products because they can involve an entire gene or a significant portion of a gene. They may play a more important role in hereditary PCa (HPC), a type of PCa that is likely due to germline changes in major genes.
In this DOD funded proposal, we propose to 1) identify germline CNPs in the genome among highrisk PCa patients using the Affymetrix 500K SNP mapping panel; and 2) test for their associations with PCa risk using family-based association tests.
BODY

Approved Statement of Work:
Aim 1. To identify germline CNPs in the genome among high-risk PCa patients using the Affymetrix 500K SNP mapping panel.
1) (Months 1-4)
Regulatory review and approval process for human studies. 2) (Months 5-12) Genotype ~500K SNPs among two affected members from each of the 206 HPC families ascertained at Johns Hopkins Hospital using the Affymetrix 500K SNP mapping panel.
We anticipate an average call rate > 95% using the default mapping algorithm setting. By applying methodology recommended by Affymetrix for improving the call rate of heterozygotes, we expect to achieve an average call rate >98%. 3) (Months 13-18) Estimate DNA copy numbers at each of these ~500K SNPs and identify germline CNPs in the genome using a computer software package, DNA-Chip Analyzer (dChip). Based on the estimated DNA copy number of these ~500K SNPs, we will identify germline CNPs using a set of criteria implemented in our scripts. For putative deletions, we will use the working criteria of a minimum of three out of four consecutive SNPs with a separation of ≥ 0.5 in CN between groups of subjects, and homozygous genotypes. A long string of consecutive homozygous SNPs (also defined as LOH) provides an important tool to identify deletions. For putative gains, we will use the working criteria of a minimum of three out of four consecutive SNPs with a separation of ≥ 0.5 in CN between groups of subjects.
Aim 2. To test for associations of identified germline CNPs with PCa risk in high-risk PCa families using family-based association tests.
4) (Months 19-20)
Select recurrent CNPs that overlap with genic regions and intergenic regions that contain highly conservative sequences for further evaluation. A genic region is defined as the region within 20 Kb upstream of the most 5' boundary, its transcribed regions including introns, and the region within 10 Kb of the most 3' boundary. CNPs located in intergenic regions and containing evolutionarily conserved sequences will also be included in the association tests. Based on our preliminary data, we expect ~43% of germline CNPs (~645) contain at least one gene. Of which, ~70% CNPs have frequency > 1% and ~30% CNPs (~200) have frequency > cancer diagnosis was verified by medical records for each affected male included in this study. Each man's age at prostate cancer diagnosis has been confirmed either through medical records or from two other independent sources. The mean age at diagnosis for men included in the study is 64.3 years. The number of families with 3, 4, and 5 or more affected individuals is 28, 50, and 128, respectively. Eighty-two percent of the families are of Caucasian descent and 9.2% are African descent.
Results. We have successfully completed genotyping for 447 subjects for hereditary prostate cancer families using Affymetrix 6.0 SNP array. We exceeded our target size of 412 using our own research funds (as part of cost share). The quality of the genotyping for these subjects is excellent.
Based on the estimated DNA copy number of these SNPs, we identified germline CNPs using a set of criteria implemented in our scripts. For putative deletions, we used the working criteria of a minimum of three out of four consecutive SNPs with a separation of ≥ 0.5 in CN between groups of subjects, and homozygous genotypes. A long string of consecutive homozygous SNPs (also defined as LOH) provides an important tool to identify deletions. For putative gains, we used the working criteria of a minimum of three out of four consecutive SNPs with a separation of ≥ 0.5 in CN between groups of subjects.
As detailed in the Supplementary Table, we have identified 1,141 germline CNVs in these samples. Among them, 118 CNVs have a frequency that is 5% more common than that in the HapMap databases, suggesting the importance of these CNVs in hereditary prostate cancer.
We are in the process of testing for association between a subset of these germline CNVs with hereditary prostate cancer risk using family-based association test. As planed in our proposed statement of work, this was our primary research activity in the last funding period.
However, we have recently focused on one particular germline CNV. By comparing allele intensities of SNP probes across the genome, a relatively large (~209 kb) germline deletion at 3p14 was observed among 6 of 39 (15.4%) Ashkenazi Jewish (AKJ) subjects included within this study population. This deletion was not observed among 408 non-AKJ samples, suggesting this is an AKJ founder mutation. For additional verification, we genotyped this deletion in AKJ HPC probands recruited at Wake Forest University (WFU), finding the deletion in 4 of 18 (22%) subjects. We confirmed that the size and boundaries are consistent in each sample by sequencing the entire deletion region among carriers. To evaluate the significance of this deletion in the general AKJ population, it was genotyped among 412 additional subjects; it was observed among 5 of 148 (3.4%) non-HPC PCa cases and 15 of 264 (5.6%) unaffected controls from McGill University. Overall, we observed the deletion in 10 of 57 AKJ HPC probands (17.5%), versus only 20 of 412 non-HPC AKJ subjects (4.9%), and this difference was significant (P = 0.002) ( Table 1) . This germline deletion resides within intron 5 of the FHIT gene, where polymorphisms have been previously associated with PCa. FHIT has also been implicated in a variety of other cancers. While our report adds to the growing evidence implicating the FHIT gene in cancer, we are the first to describe this AKJ founder germline deletion, and the first to implicate this candidate gene based upon a genomewide search. Additional confirmation of this association and functional studies are warranted. KEY RESEARCH ACCOMPLISHMENTS 1) Completed genotyping for all 447 subjects from hereditary prostate cancer families using Affymetrix 6.0 SNP array 2) Identified 1,141 germline CNVs in these subjects 3) Identified a founder germline deletion in the FHIT gene (a tumor suppressor gene) that is associated with hereditary prostate cancer risk among Ashkenazi Jews.
REPORTABLE OUTCOMES
1) Germline CNVs identified in this study population (Supplementary Table) 2) Germline deletion in the FHIT gene associated with hereditary prostate cancer risk among Ashkenazi Jews ( 
